Advertisement

Archives of Toxicology

, Volume 92, Issue 3, pp 1133–1149 | Cite as

Monitoring cytochrome P450 activity in living hepatocytes by chromogenic substrates in response to drug treatment or during cell maturation

  • Jannick Theobald
  • Xinlai Cheng
  • Ali Ghanem
  • Haristi Gaitantzi
  • Guangqi Song
  • Edda Klipp
  • Judith Wodke
  • Holger Becker
  • Ralf Mrowka
  • Katja Breitkopf-Heinlein
  • Steven Dooley
  • Stefan Wölfl
Molecular Toxicology
  • 424 Downloads

Abstract

The metabolic activity of hepatocytes is a central prerequisite for drug activity and a key element in drug–drug interaction. This central role in metabolism largely depends on the activity of the cytochrome P450 (CYP450) enzyme family, which is not only dependent on liver cell maturation but is also controlled in response to drug and chemical exposure. Here, we report the use of VividDye fluorogenic CYP450 substrates to directly measure and continuously monitor metabolic activity in living hepatocytes. We observed time- and dose-dependent correlation in response to established and putative CYP450 inducers acting through the aryl hydrocarbon receptor and drug combinations. Using repetitive addition of VividDye fluorogenic substrate on a daily basis, we demonstrated the new application of VividDye for monitoring the maturation and dedifferentiation of hepatic cells. Despite a lack of high specificity for individual CYP450 isoenzymes, our approach enables continuous monitoring of metabolic activity in living cells with no need to disrupt cultivation. Our assay can be integrated in in vitro liver-mimetic models for on-line monitoring and thus should enhance the reliability of these tissue model systems.

Keywords

Hepatocytes Fluorescence CYP450 enzymes In vitro systems Assay Liver models 

Notes

Acknowledgements

The authors would like to acknowledge the Nikon Imaging Centre, University of Heidelberg, for providing the possibility to use their microscopically setup. Special thanks to Dr. Ulrike Engel for her support in optimizing the microscopically setup and her expert assistance and technical support. The authors would like to thank Saskia Schmitteckert for the substantial help in performing the experiments.

Author contributions

JT, Experimental design, performed experiments, performed data analysis, wrote the manuscript. XC, Performed experiments, experimental design, performed data analysis. AG, Experimental design, performed experiments. HG Isolated primary murine hepatocytes, performed experiments. GS Developed and provided iHep cells. EK Participated in experimental design. JW Participated in experimental design. HB, Developed and manufactured the Chip-design. RM, Participated in experimental design. KB-H Experimental design, corrected the manuscript. SD, Supervised experiments, corrected the manuscript. SW, Supervised experiments, experimental design, corrected the manuscript.

Compliance with ethical standards

Founding sources

BMBF SysTox: FKZ 031A303E iPS-Profiler: FKZ 01EK1612C, DFG Grant program (CH 1690/2-1).

Conflict of interest

The authors declare that they have no competing financial interest.

Data availability statement

All data are is included in the manuscript.

Supplementary material

204_2017_2128_MOESM1_ESM.pdf (1.5 mb)
Supplementary material 1 (PDF 1585 KB)

References

  1. Adachi J, Mori Y, Matsui S, Takigami H, Fujino J et al (2001a) Indirubin and indigo are potent aryl hydrocarbon receptor ligands present in human urine. J Biol Chem 276:31475–31478CrossRefPubMedGoogle Scholar
  2. Adachi J, Mori Y, Matsui S, Takigami H, Fujino J et al (2001b) Indirubin and indigo are potent aryl hydrocarbon receptor ligands present in human urine. J Biol Chem 276:31475–31478CrossRefPubMedGoogle Scholar
  3. Adachi J, Mori Y, Matsui S, Matsuda T (2004) Comparison of gene expression patterns between 2,3,7,8-tetrachlorodibenzo-p-dioxin and a natural arylhydrocarbon receptor ligand, indirubin. Toxicol Sci 80:161–169CrossRefPubMedGoogle Scholar
  4. Agastin S, Giang U-BT, Geng Y, DeLouise LA, King MR (2011) Continuously perfused microbubble array for 3D tumor spheroid model. Biomicrofluidics 5:024110CrossRefPubMedCentralGoogle Scholar
  5. Andersson TB, Kanebratt KP, Kenna JG (2012) The HepaRG cell line: a unique in vitro tool for understanding drug metabolism and toxicology in human. Expert Opin Drug Metab Toxicol 8:909–920CrossRefPubMedGoogle Scholar
  6. Baptista PM, Siddiqui MM, Lozier G, Rodriguez SR, Atala A et al (2011) The use of whole organ decellularization for the generation of a vascularized liver organoid. Hepatology 53:604–617CrossRefPubMedGoogle Scholar
  7. Bhatia S, Balis U, Yarmush M, Toner M (1998) Microfabrication of hepatocyte/fibroblast co-cultures: role of homotypic cell interactions. Biotechnol Prog 14:378–387CrossRefPubMedGoogle Scholar
  8. Casper RF, Quesne M, Rogers IM, Shirota T, Jolivet A et al (1999) Resveratrol has antagonist activity on the aryl hydrocarbon receptor: implications for prevention of dioxin toxicity. Mol Pharmacol 56:784–790PubMedGoogle Scholar
  9. Cheng X, Rasque P, Vatter S, Merz KH, Eisenbrand G (2010) Synthesis and cytotoxicity of novel indirubin-5-carboxamides. Bioorg Med Chem 18:4509–4515CrossRefPubMedGoogle Scholar
  10. Cheng X, Merz KH, Vatter S, Christ J, Wolfl S et al (2014) 7,7′-Diazaindirubin—a small molecule inhibitor of casein kinase 2 in vitro and in cells. Bioorg Med Chem 22:247–255CrossRefPubMedGoogle Scholar
  11. Cheng X, Yoshida H, Raoofi D, Saleh S, Alborzinia H et al (2015a) Ethyl 2-((4-Chlorophenyl)amino)thiazole-4-carboxylate and Derivatives Are Potent Inducers of Oct3/4. J Med Chem 58:5742–5750CrossRefPubMedGoogle Scholar
  12. Cheng X, Dimou E, Alborzinia H, Wenke F, Gohring A et al (2015b) Identification of 2-[4-[(4-Methoxyphenyl)methoxy]-phenyl]acetonitrile and Derivatives as Potent Oct3/4 Inducers. J Med Chem 58:4976–4983CrossRefPubMedGoogle Scholar
  13. Cheng X, Kim JY, Ghafoory S, Duvaci T, Rafiee R et al (2016) Methylisoindigo preferentially kills cancer stem cells by interfering cell metabolism via inhibition of LKB1 and activation of AMPK in PDACs. Mol Oncol 10:806–824CrossRefPubMedPubMedCentralGoogle Scholar
  14. Chevallay B, Herbage D (2000) Collagen-based biomaterials as 3D scaffold for cell cultures: applications for tissue engineering and gene therapy. Med Biol Eng Comput 38:211–218CrossRefPubMedGoogle Scholar
  15. Chung I, Bresnick E (1994) 3-Methylcholanthrene-mediated induction of cytochrome P4501A2 in human hepatoma HepG2 cells as quantified by the reverse transcription-polymerase chain reaction. Arch Biochem Biophys 314:75–81CrossRefPubMedGoogle Scholar
  16. Ciolino HP, Yeh GC (1999) Inhibition of aryl hydrocarbon-induced cytochrome P-450 1A1 enzyme activity and CYP1A1 expression by resveratrol. Mol Pharmacol 56:760–767PubMedGoogle Scholar
  17. Ciolino HP, Daschner PJ, Yeh GC (1998) Resveratrol inhibits transcription of CYP1A1 in vitro by preventing activation of the aryl hydrocarbon receptor. Cancer Res 58:5707–5712PubMedGoogle Scholar
  18. De Montellano PRO (2005) Cytochrome P450: structure, mechanism, and biochemistry: Springer Science & Business Media, BerlinCrossRefGoogle Scholar
  19. Denison M, Heath-Pagliuso S (1998) The Ah receptor: a regulator of the biochemical and toxicological actions of structurally diverse chemicals. Bull Environ Contam Toxicol 61:557–568CrossRefPubMedGoogle Scholar
  20. Elaut G, Henkens T, Papeleu P, Snykers S, Vinken M, Vanhaecke T, Rogiers V (2006) Molecular mechanisms underlying the dedifferentiation process of isolated hepatocytes and their cultures. Curr Drug Metab 7:629–660.  https://doi.org/10.2174/138920006778017759 CrossRefPubMedGoogle Scholar
  21. Friedman MA, Woodcock J, Lumpkin MM, Shuren JE, Hass AE et al (1999) The safety of newly approved medicines: do recent market removals mean there is a problem? JAMA 281:1728–1734CrossRefPubMedGoogle Scholar
  22. Funatsu K, Ijima H, Nakazawa K, Yamashita Y, Shimada M et al (2001) Hybrid artificial liver using hepatocyte organoid culture. Artif Organs 25:194–200CrossRefPubMedGoogle Scholar
  23. Gerets HHJ, Tilmant K, Gerin B, Chanteux H, Depelchin BO et al (2012) Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol 28:69–87CrossRefPubMedPubMedCentralGoogle Scholar
  24. Godoy P, Hengstler JG, Ilkavets I, Meyer C, Bachmann A, Muller A, Tuschl G, Mueller SO, Dooley S (2009) Extracellular matrix modulates sensitivity of hepatocytes to fibroblastoid dedifferentiation and transforming growth factor beta-induced apoptosis. Hepatology 49:2031–2043.  https://doi.org/10.1002/hep.22880 CrossRefPubMedGoogle Scholar
  25. Godoy P, Hewitt N, Albrecht U, Andersen M, Ansari N et al (2013) Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol 87:1315–1530CrossRefPubMedPubMedCentralGoogle Scholar
  26. Göttel M, Le Corre L, Dumont C, Schrenk D, Chagnon M-C (2014) Estrogen receptor α and aryl hydrocarbon receptor cross-talk in a transfected hepatoma cell line (HepG2) exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol Rep 1:1029–1036CrossRefPubMedPubMedCentralGoogle Scholar
  27. Guengerich FP, Sorrells JL, Schmitt S, Krauser JA, Aryal P et al (2004) Generation of new protein kinase inhibitors utilizing cytochrome P450 mutant enzymes for indigoid synthesis. J Med Chem 47:3236–3241CrossRefPubMedGoogle Scholar
  28. Guguen-Guillouzo C, Guillouzo A (2010) General review on in vitro hepatocyte models and their applications. In: Maurel P (ed) Hepatocytes. Methods in molecular biology (Methods and protocols), vol 640. Humana Press, pp 1–40Google Scholar
  29. Hankinson O (1995) The aryl hydrocarbon receptor complex. Annu Rev Pharmacol Toxicol 35:307–340CrossRefPubMedGoogle Scholar
  30. Hengstler JG, Utesch D, Steinberg P, Platt K, Diener B et al (2000) Cryopreserved primary hepatocytes as a constantly available in vitro model for the evaluation of human and animal drug metabolism and enzyme induction. Drug Metab Rev 32:81–118CrossRefPubMedGoogle Scholar
  31. Hewitt NJ, Gómez Lechón MJ, Houston JB, Hallifax D, Brown HS et al (2007) Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 39:159–234CrossRefPubMedGoogle Scholar
  32. Hou YT, Ijima H, Matsumoto S, Kubo T, Takei T, Sakai S, Kawakami K (2010) Effect of a hepatocyte growth factor/heparin-immobilized collagen system on albumin synthesis and spheroid formation by hepatocytes. J Biosci Bioeng 110:208–216.  https://doi.org/10.1016/j.jbiosc.2010.01.016 CrossRefPubMedGoogle Scholar
  33. Huang H, Wang H, Sinz M, Zoeckler M, Staudinger J et al (2006) Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole. Oncogene 26:258–268CrossRefPubMedGoogle Scholar
  34. Kanebratt KP, Andersson TB (2008) Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies. Drug Metab Dispos 36:1444–1452CrossRefPubMedGoogle Scholar
  35. Kang YB, Sodunke TR, Lamontagne J, Cirillo J, Rajiv C et al. (2015) Liver sinusoid on a chip: Long-term layered co-culture of primary rat hepatocytes and endothelial cells in microfluidic platforms. Biotechnol BioengGoogle Scholar
  36. Kelly JH, Sussman NL (2000) A fluorescent cell-based assay for cytochrome P-450 isozyme 1A2 induction and inhibition. J Biomol Screen 5:249–253CrossRefPubMedGoogle Scholar
  37. Khetani SR, Berger DR, Ballinger KR, Davidson MD, Lin C et al (2015) Microengineered liver tissues for drug testing. J Lab Autom 20:216–250CrossRefPubMedGoogle Scholar
  38. Kim M, Lee JY, Jones CN, Revzin A, Tae G (2010) Heparin-based hydrogel as a matrix for encapsulation and cultivation of primary hepatocytes. Biomaterials 31:3596–3603.  https://doi.org/10.1016/j.biomaterials.2010.01.068 CrossRefPubMedPubMedCentralGoogle Scholar
  39. Kleinman HK, McGarvey ML, Hassell JR, Star VL, Cannon FB, Laurie GW, Martin GR (1986) Basement membrane complexes with biological activity. Biochemistry 25:312–318.  https://doi.org/10.1021/bi00350a005 CrossRefPubMedGoogle Scholar
  40. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM et al (2002) Timing of new black box warnings and withdrawals for prescription medications. JAMA 287:2215–2220CrossRefPubMedGoogle Scholar
  41. LeCluyse EL (2001) Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur J Pharm Sci 13:343–368.  https://doi.org/10.1016/S0928-0987(01)00135-X CrossRefPubMedGoogle Scholar
  42. Lee PJ, Hung PJ, Lee LP (2007) An artificial liver sinusoid with a microfluidic endothelial-like barrier for primary hepatocyte culture. Biotechnol Bioeng 97:1340–1346CrossRefPubMedGoogle Scholar
  43. Lee S-A, Choi YY, Park D, Jang JY, Kim D-S et al (2012) Functional 3D human primary hepatocyte spheroids made by co-culturing hepatocytes from partial hepatectomy specimens and human adipose-derived stem cells. PLoS One 7:e50723CrossRefPubMedPubMedCentralGoogle Scholar
  44. Levy G, Bomze D, Heinz S, Ramachandran SD, Noerenberg A et al (2015) Long-term culture and expansion of primary human hepatocytes. Nat Biotechnol 33:1264–1271CrossRefPubMedGoogle Scholar
  45. Li W, Harper PA, Tang B-K, Okey AB (1998) Regulation of cytochrome P450 enzymes by aryl hydrocarbon receptor in human cells: CYP1A2 expression in the LS180 colon carcinoma cell line after treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin or 3-methylcholanthrene. Biochem Pharmacol 56:599–612CrossRefPubMedGoogle Scholar
  46. Loskill P, Marcus SG, Mathur A, Reese WM, Healy KE (2015) μOrgano: A Lego®-like plug and play system for modular multi-organ-chips. PLoS One 10:e0139587CrossRefPubMedPubMedCentralGoogle Scholar
  47. Ma Q (2001) Induction of CYP1A1. The AhR/DRE paradigm transcription, receptor regulation, and expanding biological roles. Curr Drug Metab 2:149–164CrossRefPubMedGoogle Scholar
  48. Mandal PK (2005) Dioxin: a review of its environmental effects and its aryl hydrocarbon receptor biology. J Comp Physiol B 175:221–230CrossRefPubMedGoogle Scholar
  49. Nupura SB, Vijayan M, Solange M, Ali T, Masoumeh G et al (2016) A liver-on-a-chip platform with bioprinted hepatic spheroids. Biofabrication 8:014101CrossRefGoogle Scholar
  50. Paine AJ, Andreakos E (2004) Activation of signalling pathways during hepatocyte isolation: relevance to toxicology in vitro. Toxicol In Vitro 18:187–193.  https://doi.org/10.1016/S0887-2333(03)00146-2 CrossRefPubMedGoogle Scholar
  51. Poellinger L (2000) Mechanistic aspects the dioxin (aryl hydrocarbon) receptor. Food Addit Contam 17:261–266CrossRefPubMedGoogle Scholar
  52. Prestwich GD, Liu Y, Yu B, Shu XZ, Scott A (2007) 3-D culture in synthetic extracellular matrices: new tissue models for drug toxicology and cancer drug discovery. Adv Enzyme Regul 47:196–207CrossRefPubMedGoogle Scholar
  53. Putnam AJ, Mooney DJ (1996) Tissue engineering using synthetic extracellular matrices. Nat Med 2(7):824–826CrossRefPubMedGoogle Scholar
  54. Ramachandran SD, Schirmer K, Münst B, Heinz S, Ghafoory S et al (2015) In vitro generation of functional liver organoid-like structures using adult human cells. PLoS One 10:e0139345CrossRefPubMedPubMedCentralGoogle Scholar
  55. Ranucci CS, Kumar A, Batra SP, Moghe PV (2000) Control of hepatocyte function on collagen foams: sizing matrix pores toward selective induction of 2-D and 3-D cellular morphogenesis. Biomaterials 21:783–793.  https://doi.org/10.1016/S0142-9612(99)00238-0 CrossRefPubMedGoogle Scholar
  56. Reiners JJ, Cantu AR, Pavone A, Smith SC, Gardner CR et al (1990) Fluorescence assay for per-cell estimation of cytochrome P-450-dependent monooxygenase activities in keratinocyte suspensions and cultures. Anal Biochem 188:317–324CrossRefPubMedGoogle Scholar
  57. Rowley JA, Madlambayan G, Mooney DJ (1999) Alginate hydrogels as synthetic extracellular matrix materials. Biomaterials 20:45–53.  https://doi.org/10.1016/S0142-9612(98)00107-0 CrossRefPubMedGoogle Scholar
  58. Sato N, Meijer L, Skaltsounis L, Greengard P, Brivanlou AH (2004) Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med 10:55–63CrossRefPubMedGoogle Scholar
  59. Song G, Pacher M, Balakrishnan A, Yuan Q, Tsay H-C et al (2016) Direct reprogramming of hepatic myofibroblasts into hepatocytes in vivo attenuates liver fibrosis. Cell Stem Cell 18:797–808CrossRefPubMedGoogle Scholar
  60. Theobald J, Ghanem A, Wallisch P, Banaeiyan AA, Andrade-Navarro MA, Taskova K, Haltmeier M, Kurtz A, Becker H, Reuter S, Mrowka R, Cheng X, Wölfl S (2017) Liver-kidney-on-chip to study toxicity of drug metabolites. ACS Biomater Sci Eng.  https://doi.org/10.1021/acsbiomaterials.7b00417 Google Scholar
  61. Tong JZ, Bernard O, Alvarez F (1990) Long-term culture of rat liver cell spheroids in hormonally defined media. Exp Cell Res 189:87–92.  https://doi.org/10.1016/0014-4827(90)90260-H CrossRefPubMedGoogle Scholar
  62. Trubetskoy OV, Gibson JR, Marks BD (2005) Highly miniaturized formats for in vitro drug metabolism assays using Vivid® fluorescent substrates and recombinant human cytochrome P450 enzymes. J Biomol Screen 10:56–66CrossRefPubMedGoogle Scholar
  63. Vinken M, Papeleu P, Snykers S, de Rop E, Henkens T, Chipman JK, Rogiers V, Vanhaecke T (2006) Involvement of cell junctions in hepatocyte culture functionality. Crit Rev Toxicol 36:299–318.  https://doi.org/10.1080/10408440600599273 CrossRefPubMedGoogle Scholar
  64. Zellmer S, Schmidt-Heck W, Godoy P, Weng H, Meyer C, Lehmann T, Sparna T, Schormann W, Hammad S, Kreutz C, Timmer J, von Weizsacker F, Thurmann PA, Merfort I, Guthke R, Dooley S, Hengstler JG, Gebhardt R (2010) Transcription factors ETF, E2F, and SP-1 are involved in cytokine-independent proliferation of murine hepatocytes. Hepatology 52:2127–2236.  https://doi.org/10.1002/hep.23930 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2017

Authors and Affiliations

  • Jannick Theobald
    • 1
  • Xinlai Cheng
    • 1
  • Ali Ghanem
    • 1
  • Haristi Gaitantzi
    • 2
  • Guangqi Song
    • 6
  • Edda Klipp
    • 3
  • Judith Wodke
    • 3
  • Holger Becker
    • 4
  • Ralf Mrowka
    • 5
  • Katja Breitkopf-Heinlein
    • 2
  • Steven Dooley
    • 2
  • Stefan Wölfl
    • 1
  1. 1.Institute of Pharmacy and Molecular Biotechnology, Pharmaceutical BiologyHeidelberg UniversityHeidelbergGermany
  2. 2.Department of Medicine II, Section Molecular Hepatology, Alcohol Associated DiseasesMedical Faculty Mannheim at Heidelberg UniversityMannheimGermany
  3. 3.Theoretical Biophysics, Department of BiologyHumboldt-Universität zu BerlinBerlinGermany
  4. 4.microfluidic ChipShop GmbHJenaGermany
  5. 5.Experimentelle Nephrologie, KIM III, Universitätsklinikum JenaJenaGermany
  6. 6.Department of Gastroenterology, Shanghai Institute of Liver Disease, Zhongshan HospitalFudan UniversityShanghaiChina

Personalised recommendations